AstraZeneca AZD1775 positive results in clinical trial synod with chemotherapy and radiotherapy in combination with localized advanced pancreatic cancer
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
pancreatic cancer is one of the most deadly cancers and is also known as the "King of Cancer"In 2018, about 55,000 people in the United States will be diagnosed with pancreatic cancer, and more than 44,000 people will die from the diseaseRecently, published in Journal of Clinical Oncology, researchers at the University of Michigan found that AstraZeneca's targeted DNA damage repair mechanism, AZD1775, was combined with chemotherapy and radiotherapy to achieve positive results in the first stage of clinicaltrial(http://for newly diagnosed patients with localized advanced pancreatic cancerPhase 1 clinical trials recruited 34 patients with localized advanced pancreatic cancerIn addition to radiotherapy and the use of chemotherapydrug(http://guitar, patients receive different doses of AZD1775The primary purpose of this clinical trial is to determine the maximum tolerable dose of AZD1775 in combination therapyDuring the trial, the researchers found that this combination therapy led to a higher historical performance of the patient's OS than the use of radiotherapy alone or guitar treatmentThe median OS in this clinical trial was 22 months for all patients, while the patients treated alone with guitar Westbin had OS for 12-14 months
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
